“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients,” said
Stengone continued, “We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”
Third-Quarter 2026 Financial Results
- Cash, cash equivalents and marketable securities were
$244.5 million as ofSeptember 30, 2026 . Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. - Research and development expenses were
$16.0 million , a 45 percent increase from the third quarter of 2025. This increase was primarily driven by higher expenses related to the PIPE-791 IPF program and employee-related costs. - General and administrative expenses were
$5.0 million , a 26 percent increase from the third quarter of 2025. The increase was primarily driven by higher stock-based compensation and employee-related costs. - Net loss was
$18.7 million for the three months endedSeptember 30, 2026 , as compared to$12.8 million for the third quarter of 2025.
About
About PROPEL-IPF
The Company initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF, in the first quarter of 2026. PROPEL-IPF is a randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy, safety, tolerability and pharmacokinetics of once-daily, oral PIPE-791 with 26 weeks of treatment in approximately 324 IPF patients. The primary efficacy endpoint is the change from baseline through week 26 in absolute forced vital capacity (FVC mL). More information on this trial can be found at https://clinicaltrials.gov (NCT07284459).
Forward-Looking Statements
Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PIPE-791 and PIPE-307; the enrollment and estimated completion date of the Company’s global Phase 2 clinical trial in IPF; the Company’s cash runway; the indications, anticipated benefits of, and market opportunities for the Company’s drug candidates; the Company’s business strategies and plans; and the quotations of the Company’s management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause its actual results, events, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company’s drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials and/or require us to conduct additional studies or clinical trials or provide additional patient data, which could be costly, time-consuming and difficult to complete; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to the Company’s competitors, including the results of studies or regulatory determinations relating to the Company’s competitors; risks associated with reliance on third parties to successfully conduct clinical trials; the Company’s reliance, pursuant to a global license and development agreement, upon
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except share and per share data) | ||||||||||||||||
|
|
|
|
| ||||||||||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
Operating expenses: |
|
|
|
|
|
|
| |||||||||
Research and development | $ | 15,985 |
|
| $ | 10,992 |
|
| $ | 40,334 |
|
| $ | 38,767 |
| |
General and administrative |
| 4,981 |
|
|
| 3,940 |
|
|
| 14,964 |
|
|
| 12,177 |
| |
Total operating expenses |
| 20,966 |
|
|
| 14,932 |
|
|
| 55,298 |
|
|
| 50,944 |
| |
Loss from operations |
| (20,966 | ) |
|
| (14,932 | ) |
|
| (55,298 | ) |
|
| (50,944 | ) | |
Other income (expense): |
|
|
|
|
|
|
| |||||||||
Interest income |
| 2,362 |
|
|
| 1,957 |
|
|
| 7,207 |
|
|
| 6,236 |
| |
Other income (expense), net |
| (93 | ) |
|
| 183 |
|
|
| (216 | ) |
|
| (114 | ) | |
Total other income, net |
| 2,269 |
|
|
| 2,140 |
|
|
| 6,991 |
|
|
| 6,122 |
| |
Net loss | $ | (18,697 | ) |
| $ | (12,792 | ) |
| $ | (48,307 | ) |
| $ | (44,822 | ) | |
Other comprehensive income (loss): |
|
|
|
|
|
|
| |||||||||
Unrealized gain (loss) on marketable securities |
| (934 | ) |
|
| 118 |
|
|
| (1,767 | ) |
|
| 194 |
| |
Comprehensive loss | $ | (19,631 | ) |
| $ | (12,674 | ) |
| $ | (50,074 | ) |
| $ | (44,628 | ) | |
Net loss per share, basic and diluted (a) | $ | (0.49 | ) |
| $ | (0.45 | ) |
| $ | (1.28 | ) |
| $ | (1.68 | ) | |
Weighted-average shares of common stock outstanding, basic and diluted |
| 38,390,234 |
|
|
| 28,115,548 |
|
|
| 37,736,217 |
|
|
| 26,635,056 |
| |
| ________________ | ||
(a) | Basic and diluted per share amounts are the same for Class A and Class B shares. | |
CONDENSED BALANCE SHEETS | ||||||||
(unaudited) | ||||||||
(in thousands, except share and par value data) | ||||||||
|
|
|
|
| ||||
|
|
| ||||||
Assets |
|
|
| |||||
Current assets: |
|
|
| |||||
Cash and cash equivalents | $ | 75,198 |
|
| $ | 75,603 |
| |
Marketable securities |
| 169,286 |
|
|
| 187,293 |
| |
Prepaid expenses and other current assets |
| 5,260 |
|
|
| 5,021 |
| |
Total current assets |
| 249,744 |
|
|
| 267,917 |
| |
Property and equipment, net |
| 848 |
|
|
| 830 |
| |
Other long-term assets |
| 300 |
|
|
| 256 |
| |
Operating lease right-of-use assets |
| 6,096 |
|
|
| 7,639 |
| |
Total assets | $ | 256,988 |
|
| $ | 276,642 |
| |
Liabilities and Stockholders' Equity |
|
|
| |||||
Current liabilities: |
|
|
| |||||
Accounts payable | $ | 641 |
|
| $ | 1,016 |
| |
Accrued expenses |
| 4,663 |
|
|
| 6,387 |
| |
Current portion of operating lease liabilities |
| 2,724 |
|
|
| 2,341 |
| |
Total current liabilities |
| 8,028 |
|
|
| 9,744 |
| |
Operating lease liabilities, net of current portion |
| 3,542 |
|
|
| 5,909 |
| |
Total liabilities |
| 11,570 |
|
|
| 15,653 |
| |
Commitments and contingencies |
|
|
| |||||
Stockholders' equity: |
|
|
| |||||
Class A common stock, |
| 35 |
|
|
| 31 |
| |
Class B common stock, |
| 4 |
|
|
| 6 |
| |
Preferred stock, |
| — |
|
|
| — |
| |
Additional paid-in-capital |
| 472,573 |
|
|
| 438,072 |
| |
Accumulated deficit |
| (225,687 | ) |
|
| (177,380 | ) | |
Accumulated other comprehensive income (loss) |
| (1,507 | ) |
|
| 260 |
| |
Total stockholders' equity |
| 245,418 |
|
|
| 260,989 |
| |
Total liabilities and stockholders' equity | $ | 256,988 |
|
| $ | 276,642 |
| |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103547642/en/
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: